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Radiotherapy induced xerostomia: a randomised, double-blind, controlled trial of 
Visco-ease oral spray versus placebo in head and neck cancer patients 
 
ABSTRACT  
Background 
Radiotherapy induced xerostomia (RIX) is a common and untreatable side effect of 
head and neck (H&N) radiotherapy (RT). 
Visco-ease is a novel product made from lamellar body mimetics which reduces the 
viscosity of saliva ex-vivo. 
The purpose of this 1st-in-man study was to evaluate safety and effectiveness of 
Visco-ease mouth spray in the treatment of RIX. 
Methods 
43 patients with H&N cancer were randomised to receive Visco-ease or placebo oral 
spray. The Groningen Radiotherapy Induced Xerostomia (GRIX) questionnaire was 
completed weekly.  The primary endpoint was change in GRIX score from baseline to 
end of treatment.  
Results 
There was no difference in GRIX scores between the two groups. 
There were no device related SAEs in either group. 
Conclusion 
Visco-ease oral spray was safe and tolerable but was no better than placebo in 
reducing RIX in patients undergoing RT or CRT for H&N cancer as currently 
formulated. 
 
Keywords 
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INTRODUCTION 
Radiotherapy (RT) induced xerostomia (RIX) is the most commonly reported late and 
permanent side effect of RT for head and neck cancer (HNC)1 and impairs patients’ 
quality of life (QoL), 2,3  causing discomfort, taste alteration, speech and swallowing 
difficulties and dental caries. 4 
Despite advances in radiation technology, clinically significant xerostomia affects 
around 40% of patients at 12 months post treatment. 5, 6  Furthermore, the changing 
epidemiology of HNC due to a rise in human papilloma virus (HPV) driven 
oropharyngeal cancer means patients are often younger7 with a significantly 
improved response to treatment and overall survival, 8,9 therefore will live much 
longer with the consequences of treatment. 10, 11   
There is no effective treatment for RIX and a Cochrane review concluded that 
‘randomized controlled trials of topical interventions for dry mouth are required to 
provide evidence to guide clinical care’. 12 
 
Lamellar bodies have surface active properties and are an essential lubricant of the 
body’s tissues, preventing mucosal surfaces from sticking to each other and sticky 
secretions, like thick saliva, from congesting the hollow organs.  
Visco-ease, formerly known as LMS-611, is a multi-lipid mimetic of a naturally 
occurring lamellar body.  Pre-clinical work suggested that Visco-ease may restore the 
thick, sticky saliva seen after RT to the H&N to more fluid saliva like that seen prior 
to RT. 13   
 
The purpose of this study was to evaluate the safety and effectiveness of Visco-ease 
mouth spray for the treatment of RIX in HNC patients.  This was a first-in-man study 
of the device.  In line with published recommendations 14 it was felt that patient 
reported outcomes were the most critical measures of effectiveness of Visco-ease. 
The validated Groningen Radiotherapy Induced Xerostomia (GRIX) questionnaire 15 
was chosen to evaluate patient reported RIX during this study. 
The primary endpoint was change in GRIX score from baseline to end of treatment 
and was compared between Visco-ease and placebo. Secondary objectives were to 
collect safety outcomes for each group and frequency of administration of the oral 
spray.  
 
MATERIALS AND METHODS 
Participants 
Patients with HNC, who were scheduled to commence radical RT or chemoRT (CRT) 
as primary treatment, were recruited to this randomised, double-blind, and placebo 
controlled study.  
Eligible patients were aged 18 years or older and were judged to be at high risk of 
RIX. Exclusion criteria included known pre-existing xerostomia, use of any 
investigational drug or product within 30 days, primary surgery for HNC and known 
allergies to egg, soya, or lanolin based products. 
 
Randomisation and blinding 
Patients were randomly assigned to receive Visco-ease or placebo (0.9% 
physiological saline) oral spray on a 2:1 basis. Independent randomisation was via an 
interactive web response system at The Robertson Centre for Biostatistics. Neither 
the patient nor investigators were informed of the treatment allocation.  All 
treatment and placebo kits were presented in an identical manner to protect the 
study blinding. 
 
Procedures     
All patients received radical RT or CRT delivered with volumetric modulated arc 
therapy (VMAT). Gross tumour and the entirety of involved nodal levels received 
65Gy/30# over 6 weeks. Prophylactic dose to areas considered at high risk of occult 
disease was 54Gy/30# over 6 weeks.  Selection and delineation of target volumes 
was carried out according to international guidelines. 16 Cisplatin was delivered at 
100mg/m2 on day 1 and 22 of treatment for those receiving concurrent 
chemotherapy. 
 
Patients were asked to use the oral spray (Visco-ease or placebo) as required but at 
least one spray, twice daily during the course of their RT, beginning on the first day 
of treatment. They were instructed to deliver the spray under the tongue then to 
move the fluid around the mouth.  The oral spray was initiated prior to the patients 
developing RIX to allow assessment of the tolerability of the product independent of 
the subsequent symptoms. Patients were assessed weekly during RT and 
concomitant medications and adverse events recorded. Patient reported xerostomia 
scores, using the GRIX questionnaire, were collected weekly.  Subjects were also 
asked to keep a daily diary, recording the times and frequency of oral spray 
administration. 
 
Statistical analysis 
The primary endpoint for the study was change in GRIX score from baseline to week 
6 of RT. Previous work demonstrated that the changes in GRIX scores over 6 weeks 
of RT were approximately normally distributed in untreated patients, with a mean of 
65.2 and a standard deviation of 22.3. 13  
For the sample size calculation it was assumed that the mean change in the placebo 
group is 65 and the mean change in the treated group is 35. The standard deviation 
was assumed to be 23 in both groups. Group allocation was 2:1, with two subjects 
receiving Visco-ease spray for one subject receiving placebo. 
The sample size calculation was based on comparing change in GRIX scores from 
baseline to week 6 of RT between the two groups using a two-sided two sample t-
test, with significance level 0.05. The number of subjects required to achieve a 
power of 90% was 30, 20 subjects in the group receiving Visco-ease and 10 in the 
placebo group. The sample size calculation was carried out using Proc Power in SAS 
9.3. To allow for a dropout rate of 25%, 41 subjects were required, 27 randomised to 
the group receiving Visco-ease and 14 to the placebo group. 
 
Baseline characteristics were summarised overall and for each treatment group 
using mean, standard deviation (SD), minimum and maximum for continuous 
variables, and using counts and percentages for categorical variables. 
 
Statistical analysis of the treatment effect, on the primary outcome of change in 
GRIX scores from baseline to end of treatment, was assessed using linear regression 
adjusting for baseline GRIX score.  
All analyses were performed using the statistical software platform R. 17 
 
 
RESULTS 
Ethics approval and consent to participate 
The protocol was approved by West of Scotland Research Ethics Committee 4, 
(15/WS/0281) and MHRA (CI/2015/0053). Written informed consent was obtained 
from all participants. The study was sponsored by NHS Greater Glasgow and Clyde.  
The study was conducted according to the principles of Good Clinical Practice and 
the Declaration of Helsinki.  
 
Participants 
43 patients (15 in the placebo group and 28 in the Visco-ease group) were recruited 
to the study between March and December 2016 from 62 patients screened, see 
figure 1, CONSORT diagram  
 
Baseline Demographics 
Table 1 shows the patient and tumour characteristics and treatment details.  The 
patient demographics appeared well balanced between the two groups. Mean age 
was 59 years, almost 90% of participants were male and all had SCC. Oropharynx was 
the most common subsite with 70.8% of tumours HPV-positive across both groups. 
The most notable imbalance between the groups was in tumour staging. A higher 
proportion of patients in the Visco-ease group had stage III or IV disease or higher T 
staging compared to the placebo group. The higher use of concurrent CRT in the 
Visco-ease group is likely to reflect this more advanced disease stage. During the 
course of the study, withdrawals from both groups meant that this imbalance in 
disease stage increased further.  
 
Patient reported xerostomia scores 
Weekly GRIX scores are shown in figure 2. Patient reported xerostomia increases 
throughout RT. There was no statistically significant difference (calculated using 
ANOVA) between each group for mean clinic GRIX score at any time point.  
The change in GRIX scores from baseline to end of treatment were compared 
between the treatment groups using linear regression adjusting for baseline GRIX 
score. No relationship was found (effect = -1.26, CI -21.77 to 19.24, p-value = 0.90) 
 
Frequency of oral spray administration 
The number of sprays used each day is shown in figure 3 for each group.  
The number of sprays used increases initially during RT but then decreases again 
towards the end of treatment.  
 
Safety endpoints 
The occurrence of ‘at least possibly device related’ serious adverse events (SAEs) 
were monitored throughout the study. No such episodes were recorded for either 
group.  
The number of participants with ‘at least one adverse event (AE) or SAE was 
compared between the 2 groups as shown in table 2. There was no statistically 
significant difference in percentage of participants with an AE or SAE between the 2 
groups. The relatively high frequency of AEs and SAEs reflects the significant acute 
toxicity this group of patients experience with RT or CRT and was anticipated. 
 
DISCUSSION 
Patient characteristics are as expected for a cohort undergoing primary RT for HNC. 
Patient reported xerostomia scores increase during RT. Previous work demonstrated 
a mean increase in GRIX score of 65.2 during 6 weeks of RT.13 In this study, the mean 
increase in the Visco-ease group was less at 41.6. What was unexpected, however, 
was a similar increase in GRIX scores in the placebo arm of only 41.5.  Laboratory 
work has already demonstrated no efficacy of the placebo (physiological saline) on 
the visco-adhesive properties of RIX saliva. 13  The smaller-than-expected increase in 
GRIX scores in the placebo group may be due to the well recognised placebo effect. 
It is also feasible that the subjective symptom of RIX was genuinely improved with 
the use of oral saline spray compared to no intervention.  Our findings confirm the 
importance of including a placebo for comparison when investigating new 
treatments for RIX.  Some previous studies assessing interventions for RIX have not 
included a placebo arm. 18,19 Had the placebo group not been included we may have 
assumed the smaller increase in GRIX scores observed compared to the historical 
controls was clinically significant as the scores were around 36% less than recorded 
previously in the same setting (41.6 Vs 65.2). 
Comparison between GRIX scores in the placebo and Visco-ease groups failed to 
show a significant difference at any time point. In particular the primary efficacy 
endpoint of a 30-point reduction in the GRIX score with Visco-ease compared to 
placebo was not met. This is partly due to lower than anticipated GRIX scores in the 
placebo group as discussed above.  Furthermore, 4 patients (1 receiving Visco-ease 
and 3 placebo) did not develop RIX (as defined by not reaching a GRIX score of 30 or 
more at any point during the study) making it impossible for their scores to meet the 
primary efficacy endpoint. 
The documented use of oral spray shows an increase in number of sprays used 
during the course RT with a reduction in use over the final 1-2 weeks of treatment. 
As no formal evaluation was made of compliance it is unclear if the documented 
frequency of use demonstrated true compliance with the oral spray or simply failure 
to record its use as time went on. Good compliance in the early weeks of use 
suggests good tolerability of the product. 
No difference was demonstrated in the frequency of AEs or SAEs between the 
Visco-ease and placebo groups. No device related AEs were documented for either 
group during the study. Therefore, this first-in- man study of Visco-ease has 
demonstrated a very safe toxicity profile.  
It is disappointing that the study did not meet the primary efficacy endpoint of a 
significant reduction on RIX in the treatment Vs placebo group. Our results 
demonstrate some of the difficulties in carrying out a study of a new intervention for 
RIX. It is widely accepted that patient reported outcomes for xerostomia are the 
most important measure of judging success of an intervention for this symptom. 14 
Physician reported scores or measures such as salivary flow do not necessarily 
demonstrate correlation with the symptom experienced by the patient. 1, 20  
However, RIX is a very subjectively reported symptom, 14  making it a difficult metric 
to account for when designing a study such as this.  
This study was carried out in patients currently receiving RT for HNC. RIX is often 
considered a late or chronic toxicity from RT to the H&N, but has also been 
demonstrated to occur as an acute toxicity, during treatment.13, 21 The acute group 
of patients were chosen from a safety perspective as this medical device had not 
been tested in humans before and therefore it was important that we were able to 
monitor its effects closely in a group that were already attending hospital on a 
frequent (daily) basis. Patients who have completed RT generally attend as 
outpatients on a monthly or less frequent basis for ongoing assessment. Additional 
visits required for safety monitoring within the study were felt to be an unjustified 
burden in this group.  It is likely, however, that the acute RIX patients comprise a 
group with a significantly higher symptom burden and poorer QoL than the chronic 
group. 22 Symptoms will include not only RIX but other acute toxicities seen with CRT 
and RT to the H&N such as mucositis, dysphagia, skin reaction, pain, anorexia, 
weight loss, nausea and vomiting. It is likely that modifying one acute symptom will 
make little difference to the global QoL experienced by the patient, as overall, that 
QoL remains much poorer than at baseline. Now that the safety profile of Visco-ease 
has been demonstrated, further studies will be carried out in post-RT patients with 
established RIX, who are likely to have much more stable symptoms. As a result 
Visco-ease may demonstrate efficacy in the chronic RIX population and this area will 
be the focus of future work. 
During randomisation, no stratification was made for any baseline patient, tumour 
or treatment characteristic, which produced a tendency for patients in the 
Visco-ease group to have Stage III and IV cancer and greater frequency of CRT. 
Unfortunately, given the nature of withdrawals during the study these imbalances 
were even more pronounced at the end of treatment.  Higher stage disease will 
inevitably result in larger irradiated volumes being treated to a higher dose. 
Concurrent CRT is well known to cause increased toxicity compared to RT alone. 23, 24 
It seems likely therefore that the Visco-ease group will have experienced a higher 
symptom burden than the placebo group which may have skewed the results. 
Stratification for all potentially confounding variables in this study (patient age, 
concomitant medication, smoking/alcohol history, tumour stage and treatment: RT 
Vs chemoRT) would have meant that a larger sample size were required. This was 
felt to be inappropriate by the investigators given the 1st-in-man nature of the study. 
Exploratory, post hoc analyses were carried out after these initial results were 
examined and the difficulties described above were considered. 
All patients who failed to reach a GRIX clinic score of 30 or more were excluded. 
Multi-variate regression was used to identify the factors which had the greatest 
influence on GRIX scores. These were tumour staging, concurrent CRT, MST use and 
study treatment. When using the restricted population, after adjusting for the 
potentially confounding covariates there appeared to be a positive effect of 
Visco-ease compared to placebo in reducing GRIX scores. This supplementary data 
will only be used to inform the design of future clinical studies and not to make any 
efficacy claims. It does however suggest that a signal may be detected with an 
appropriately designed study and this is worth progressing. An alternative 
formulation of Visco-ease e.g. oral rinse rather than spray is also under consideration 
for future studies. 
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FIGURE LEGENDS 
Figure 1, Trial Profile, CONSORT flow diagram 
Figure 2, Weekly GRIX Clinic Scores, blue = placebo, red = Visco-ease  
Figure 3 Number of Sprays Used per Day 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screened 
n=62
Allocated to Visco-ease n=28
-Received allocated intervention n=25
-Did not receive allocated intervention n=3
(1 patient died prior to tx starting,  2 -change of tx 
plan so ineligible)
Discontinued intervention
n=5
(1 found to be ineligible due to 
pre-exisiting xerostomia, 4 
patient choice)
Analysed n=19
Excluded from analysis due to 
protocol violation n=1
Allocated to Placebo n=15
-Received allocated intervention n=14
-Did not receive allocated intervention n=1
(patient withdrew consent for study)
Discontinued intervention 
n=2
(both patient choice)
Analysed
n=12
Declined to participate
n=19
 
 
 
  Placebo (n=14) 
Number (%) 
Visco-ease (n=25) 
Number (%) 
Age (years) Mean 
Range 
61.6 
50.5 – 78.2 
58.0 
41.3 – 70.3 
Gender Male 
Female 
13 (92.9%) 
1    (7.1%) 
22 (88.0%) 
3   (12.0%) 
Sub Site Oropharynx 
Larynx 
Hypopharynx 
Nasopharynx 
UKP 
9 (64.3%) 
3 (21.4%) 
1 (7.1%) 
1 (7.1%) 
0 (0%) 
15 (60.0%) 
5 (20.0%) 
2 (8.0%) 
0 (0%) 
3 (12.0%) 
Pathology SCC 14 25 
T staging T0-T1-T2 
T3-T4 
12 (85.7%) 
2 (14.3%) 
20 (80.0%) 
5 (20.0%) 
Stage I-II 
III-IV 
4 (28.6%) 
10 (71.4%) 
3 (12.0 %) 
22 (88.0%) 
Concurrent CRT Yes 
No 
7 (50.0%) 
7 (50.0%) 
17 (68.0%) 
8 (32.0%) 
Table 1 Baseline Demographics for APT 
 
 
Event 
 
Placebo 
(n=14) 
 
Visco-ease 
(n=25) 
p-value 
(Fishers 
exact test) 
Non serious AE 4 (28.6%) 6 (24.0%) 1.000 
SAE 6(42.9%) 14 (56.0%) 0.5145 
Table 2. Comparison between treatment groups of subjects with at least 1 AE or 
SAEs (APT) 
 
